Výsledky vyhledávání - "Michael Teufel"

Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies

Autor: Lynley V. Marshall, Irene Jiménez, Andrew D.J. Pearson, Udo Mueller, Adriaan Cleton, Bart Ploeger, Michael Teufel, Patricia Maeda, Sarah Schlief, Bruce Morland, Andrea C. Agostinho, Gilles Vassal, Jasmine Kincaide, Birgit Geoerger, Didier Frappaz

Publikováno v: European Journal of Cancer. 153:142-152

Background This phase 1 study evaluated safety, pharmacokinetics (PK), maximum tolerated dose (MTD), and antitumour activity of regorafenib in paediatric patients with solid tumours. Patients and methods Patients (aged 6 months to Results Forty-one p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6ce50d56d650acd3c02420f1172c518
https://doi.org/10.1016/j.ejca.2021.05.023

Zobrazit plný text záznamu

Efficacy and safety of the MDM2–p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials

Autor: Noboru Yamamoto, Anthony W. Tolcher, Navid Hafez, Iwona Lugowska, Rodryg Ramlau, Mrinal M. Gounder, Junxian Geng, Jian Li, Michael Teufel, Angela Maerten, Patricia LoRusso

Publikováno v: Journal of Clinical Oncology. 41:543-543

543 Background: Standard-of-care treatment for advanced biliary tract cancer (BTC) is chemotherapy and outcomes remain poor; hence, there is a clinical need for effective targeted treatments. As MDM2 is a negative regulator of the tumor suppressor p5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f193cb2f42d6b76c200b32c743d77706
https://doi.org/10.1200/jco.2023.41.4_suppl.543

Zobrazit plný text záznamu

Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial

Autor: Michael Jeffers, Christian Kappeler, Iris Kuss, Georg Beckmann, Daniel H. Mehnert, Johannes Fredebohm, Michael Teufel

Publikováno v: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 25(3)

Background In the phase 3 GRID trial, regorafenib improved progression-free survival (PFS) independent of KIT mutations in exons 9 and 11. In this retrospective, exploratory analysis of the GRID trial, we investigated whether a more comprehensive KIT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8600d24b111ec7ca7b4e8c16294ddb2a
https://pubmed.ncbi.nlm.nih.gov/35050442

Zobrazit plný text záznamu

Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma

Autor: Richard S. Finn, Henrik Seidel, Gerold Meinhardt, Josep M. Llovet, Jordi Bruix, Karl Köchert, Michael Teufel

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona

Background & Aims In a phase 3 trial (RESORCE), regorafenib increased overall survival compared with placebo in patients with hepatocellular carcinoma (HCC) previously treated with sorafenib. In an exploratory study, we analyzed plasma and tumor samp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f4b1a81755c20399d09883e3a867e91
https://doi.org/10.1053/j.gastro.2019.01.261

Zobrazit plný text záznamu

Abstract CT514: A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors

Autor: Elena Élez, Heinz-Josef Lenz, Maja de Jonge, Rona Yaeger, Toshihiko Doi, Linda Pronk, Michael Teufel, Kristell Marzin, Josep Tabernero

Publikováno v: Cancer Research. 82:CT514-CT514

Background: Ligand-dependent Wnt signaling, mediated by LRP5/6, is highly activated in a subset of solid tumors. Activation leads to accumulation of intracellular β-catenin and expression of β-catenin-dependent genes that promote cancer cell prolif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26cefd192958d185611c656e333873f3
https://doi.org/10.1158/1538-7445.am2022-ct514

Zobrazit plný text záznamu

A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors

Autor: Noboru Yamamoto, Navid Hafez, Anthony W. Tolcher, Michael Teufel, Junxian Geng, Liz Svensson, Mehdi Lahmar, Mrinal M. Gounder

Publikováno v: Journal of Clinical Oncology. 40:3095-3095

3095 Background: Preclinical data show that combining a murine double minute 2–tumor protein 53 (MDM2–p53) antagonist with immune checkpoint inhibitors produces anti-tumor effects in multiple tumor types. This Phase Ia/Ib study (NCT03964233) is a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::273f47695b07f514e0bf92ab5e69d278
https://doi.org/10.1200/jco.2022.40.16_suppl.3095

Zobrazit plný text záznamu

Continuous adaption through real data analysis turn simulation models into digital twins

Autor: Andreas Kuhnle, Gisela Lanza, Michael Teufel, Leonard Overbeck, Oliver Brützel, Nicole Stricker

Digital twins of production systems enable new forms of production control, flexibility and continuous improvement. While off-the-shelf software for discrete-event simulation permits the fast implementation of rough simulation models with sufficient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96df0210c7ab7d006eecdcdc48a46844

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání